Ascorbic Acid
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Ascorbic Acid: Non-syndromic esophageal malformation
One-Sentence Summary
Ascorbic acid (vitamin C) is an essential water-soluble vitamin with antioxidant activity and a cofactor role in collagen synthesis. The TxGNN model predicts it may be relevant to non-syndromic esophageal malformation, with a score of 0.9996. However, no clinical trials and no publications support this prediction, so it is a model output only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Non-syndromic esophageal malformation |
| TxGNN Prediction Score | 0.9996 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available for this drug. Ascorbic acid is generally known as an antioxidant and as a cofactor for hydroxylase enzymes involved in collagen stabilisation.
For this prediction, no mechanistic link has been identified. Non-syndromic esophageal malformation is a congenital structural condition, and there is no plausible way an antioxidant vitamin would correct a developmental anatomical defect. The very high TxGNN score is not backed by any trial or publication, and it should be read as a computational signal rather than evidence of benefit.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Licence 674L | Not recorded | Not recorded | Not recorded |
The local data hold one single-ingredient licence, and it is currently valid. Product name, dosage form and indication text are not recorded for it.
Safety Considerations
Label-based warnings and contraindications are not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for safety information.
Drug interactions: 25 interactions were identified in total; the 20 listed in the data include these main ones:
- Moderate: amphetamine, dextroamphetamine, lisdexamfetamine, metamfetamine, benzphetamine, aluminium hydroxide, bortezomib, deferoxamine.
- Minor: paclitaxel, cisplatin, doxorubicin (including liposomal), pseudoephedrine, ephedrine, ethinylestradiol, flecainide, fluphenazine, indinavir, mexiletine.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting trials or literature, no plausible mechanism for correcting a congenital structural malformation, and an evidence level of L5. The high model score alone does not justify further investment.
To proceed, the following is needed:
- Any biological rationale linking ascorbic acid to oesophageal development, supported by preclinical data
- Mechanism of action data for the drug
- Safety information from the TGA-approved Product Information, including contraindications and warnings
- Product-level details (dosage form, indication text) for ARTG entry 674L
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.